Evofem Biosciences, Inc. Affirms 2022 Guidance. Evofem continues to expect net product sales in the range of $30 to $35 million for its 2022 fiscal year, representing 264% to 325% growth year-over-year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0155 USD | +2.65% | +1.31% | -75.78% |
1st Jan change | Capi. | |
---|---|---|
-75.78% | 1.01M | |
+35.01% | 709B | |
+31.06% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.77% | 239B | |
+9.44% | 211B | |
-3.80% | 203B | |
+10.77% | 171B |
- Stock Market
- Equities
- EVFM Stock
- News Evofem Biosciences, Inc.
- Evofem Biosciences, Inc. Affirms 2022 Guidance